+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Drug Repurposing Market Outlook 2026-2034: By Therapeutic Area, Development Stage, Drug Molecule Type, Route of Administration, End User

  • PDF Icon

    Report

  • 160 Pages
  • November 2026
  • Region: Global
  • OG Analysis
  • ID: 6273062
UP TO OFF until Jan 01st 2027
The Drug Repurposing Market is estimated at USD 39.3 billion in 2026 and is forecast to reach USD 49.7 billion by 2034, at a CAGR of 3.0% during 2026-2034. The Drug Repurposing Market covers research and development for new uses of existing medicines. Demand is linked to efficient exploration of therapeutic opportunities. Development priorities include data-guided screening and validation partnerships. Adoption must account for biological validation and intellectual-property constraints. Buyers assess evidence, development feasibility and commercial relevance. The geographic assessment considers American research programs, European specialist suppliers and Asian laboratory investment. The study examines By Therapeutic Area, By Development Stage, By Drug Molecule Type, relating these analytical views to customer needs, supplier capabilities and the practical requirements of market participation. The competitive assessment considers BenevolentAI, Healx, Insilico Medicine, alongside the other companies mentioned, with attention to their roles, product positioning and access to relevant customers.

Key Takeaways

  • Demand drivers: Demand is linked to efficient exploration of therapeutic opportunities. Purchasing depends on evidence, development feasibility and commercial relevance, with different users balancing technical value and implementation effort. This makes the relationship between end-use activity and actual supplier orders important to understanding commercial prospects.
  • Technology direction: Data-guided screening and validation partnerships provides a focus for development. Practical adoption still depends on evidence, development feasibility and commercial relevance. Buyers need a clear match between the proposed improvement and their operating requirements, rather than relying on technical novelty as proof of value.
  • Key market distinctions: The report examines By Therapeutic Area: Oncology, CNS Disorders, Cardiovascular Diseases; By Development Stage: Pre-clinical, Phase I, Phase II; By Drug Molecule Type: Small-molecule Drugs, Biologics & Peptides. These divisions should be read as different analytical views rather than added together. Customer requirements and adoption barriers can vary materially between categories, making application-level assessment important when comparing opportunities.
  • Adoption challenges: Biological validation and intellectual-property constraints can limit deployment or lengthen purchasing decisions. Their importance varies with the use case and customer resources. Commercial planning should account for qualification, implementation and support requirements before assuming that demand will translate directly into sustained adoption.
  • Competitive positioning: The company coverage includes BenevolentAI, Healx, Insilico Medicine. Competitive assessment focuses on evidence, development feasibility and commercial relevance. The relevant distinction is each participant’s role and offering, since suppliers, technology partners and service providers do not necessarily compete across the same activities.
  • Geographic dynamics: Geographic considerations include American research programs, European specialist suppliers and Asian laboratory investment. These settings differ in customer priorities, supply capabilities and purchasing structures. Market-entry decisions therefore depend on local adoption conditions and channel access, with customer requirements and service reach assessed for each covered location.
  • Buyer economics: Selection depends on evidence, development feasibility and commercial relevance. Development budgets must account for experimental validation, analytical methods and process transfer. Procurement depends on the intended research or manufacturing task, making reproducibility and usable documentation more informative than unsupported claims of broad clinical benefit.
  • Supply and delivery: Demand linked to efficient exploration of therapeutic opportunities requires consistent delivery. Specialist developers, research suppliers and manufacturing partners perform different roles. Reliable methods, defined specifications and traceable materials help support repeatable work, while technical support and controlled changes matter when projects move between laboratories or development stages.
  • Routes to market: Research partnerships, specialist procurement and development-service contracts shape commercial access for Drug Repurposing. Requirements involving research governance, material traceability, quality documentation and development-stage oversight also affect participation. Suppliers need to understand customer approval processes and channel responsibilities when selecting an expansion strategy or developing a differentiated offering.
  • Strategic opportunities: Development around data-guided screening and validation partnerships creates a basis for differentiation. Specialized platforms and application-specific services can address unmet development needs. Commercial opportunities depend on credible experimental evidence and a clear customer use case, with research activity distinguished from authorized therapeutic sales and claims matched to the actual stage of development.

Market Segmentation

By Therapeutic Area

  • Oncology
  • CNS Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Metabolic Disorders

By Development Stage

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Approved / Marketed

By Drug Molecule Type

  • Small-molecule Drugs
  • Biologics & Peptides

By Route of Administration

  • Oral
  • Injectable
  • Topical / Others

By End User

  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

Drug Repurposing Market Analytics

The report applies Porter’s Five Forces, value-chain mapping and scenario analysis to the Drug Repurposing Market. Supply and demand are examined alongside customer requirements, substitute offerings and adjacent market influences. Analysis of efficient exploration of therapeutic opportunities and data-guided screening and validation partnerships helps explain the conditions supporting adoption. Pricing and procurement dynamics are considered in relation to evidence, development feasibility and commercial relevance. Service delivery, access conditions and the role of implementation partners are considered where relevant. The framework connects research governance, material traceability, quality documentation and development-stage oversight with market opportunities and risks, helping readers evaluate operating assumptions and the potential consequences of changing industry conditions.

Drug Repurposing Market Competitive Intelligence

Competitive Landscape

Competition centers on application expertise, portfolio specialization and partnerships that improve evidence, development feasibility and commercial relevance. The company coverage includes BenevolentAI, Healx, Insilico Medicine. The report examines how participants use data-guided screening and validation partnerships to differentiate offerings and respond to biological validation and intellectual-property constraints. Commercial approaches are assessed through product positioning, integration support, geographic reach and customer relationships. Opportunities linked to efficient exploration of therapeutic opportunities provide context for comparing focused specialists with broader suppliers. Coverage distinguishes direct competitors from affiliated businesses, platform owners and supporting partners where relevant. This helps readers evaluate supplier fit, customer access and collaboration opportunities across the market’s value chain.

Companies Mentioned

  • BenevolentAI
  • Healx
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Schrödinger
  • Atomwise
  • GSK
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • Roche
  • Sanofi
  • Bristol Myers Squibb
  • AstraZeneca
  • Bayer
  • Merck & Co.
  • Takeda

Countries Covered

North America - Drug Repurposing Market data and outlook to 2034

  • United States
  • Canada
  • Mexico

Europe - Drug Repurposing Market data and outlook to 2034

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • BeNeLux
  • Russia
  • Sweden

Asia-Pacific - Drug Repurposing Market data and outlook to 2034

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam

Middle East and Africa - Drug Repurposing Market data and outlook to 2034

  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt

South and Central America - Drug Repurposing Market data and outlook to 2034

  • Brazil
  • Argentina
  • Chile
  • Peru
Additional country data and analysis can be included on demand.

Research Methodology

This study combines primary inputs from industry experts across the Drug Repurposing value chain with secondary data from associations, government publications, trade databases and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation and scenario planning, are applied to support market sizing and forecasting. Market definitions and the roles of different participants are considered when comparing inputs and interpreting the outlook.

Key Questions Addressed

  • What is the current and forecast outlook for the Drug Repurposing Market across the covered geographies?
  • How do efficient exploration of therapeutic opportunities influence customer needs and purchasing decisions?
  • What opportunities and barriers are associated with data-guided screening and validation partnerships?
  • How do customers assess evidence, development feasibility and commercial relevance?
  • How are companies responding to biological validation and intellectual-property constraints?
  • Which applications, customer groups and partnership models offer relevant routes to market?
  • How do policy, supply conditions and competitive capabilities affect strategic choices?

Your Key Takeaways from the Drug Repurposing Market Report

  • Drug Repurposing market size and growth outlook across the covered regions and countries
  • Market-specific trends, demand drivers, adoption challenges and opportunities
  • Assessment of By Therapeutic Area, By Development Stage, By Drug Molecule Type, By Route of Administration, By End User
  • Commercial implications of data-guided screening and validation partnerships
  • Competitive positioning and capabilities of the companies mentioned
  • Purchasing considerations involving evidence, development feasibility and commercial relevance
  • Geographic and supply-chain factors associated with American research programs, European specialist suppliers and Asian laboratory investment
  • Porter’s Five Forces, value-chain analysis and scenario-based strategic assessment
  • Relevant market developments and their implications for business planning

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Market Definition and Revenue Scope
1.2. Key Findings and Strategic Outlook
2. Research Scope and Methodology
2.1. Data Sources and Triangulation
2.2. Forecast Assumptions and Boundaries
3. Market Dynamics
3.1. Market-specific Demand Drivers
3.2. Technology and Product Trends
3.3. Adoption Challenges
3.4. Commercial Opportunities
4. Market Analytics
4.1. Value-chain Analysis
4.2. Porter’s Five Forces
4.3. Pricing and Procurement Dynamics
5. Global Drug Repurposing Market Size and Outlook, 2026-2034
5.1. Total Global Market Revenue
5.2. By Therapeutic Area
5.2.1. Oncology
5.2.2. CNS Disorders
5.2.3. Cardiovascular Diseases
5.2.4. Infectious Diseases
5.2.5. Metabolic Disorders
5.3. By Development Stage
5.3.1. Pre-clinical
5.3.2. Phase I
5.3.3. Phase II
5.3.4. Phase III
5.3.5. Approved / Marketed
5.4. By Drug Molecule Type
5.4.1. Small-molecule Drugs
5.4.2. Biologics & Peptides
5.5. By Route of Administration
5.5.1. Oral
5.5.2. Injectable
5.5.3. Topical / Others
5.6. By End User
5.6.1. Pharmaceutical & Biotech Companies
5.6.2. Academic & Research Institutes
5.6.3. Contract Research Organizations (CROs)
6. North America Drug Repurposing Market Outlook
6.1. Regional Revenue and Forecast
6.2. By Therapeutic Area
6.3. By Development Stage
6.4. By Drug Molecule Type
6.5. By Route of Administration
6.6. By End User
6.7. Country-level Analysis
7. Europe Drug Repurposing Market Outlook
7.1. Regional Revenue and Forecast
7.2. By Therapeutic Area
7.3. By Development Stage
7.4. By Drug Molecule Type
7.5. By Route of Administration
7.6. By End User
7.7. Country-level Analysis
8. Asia-Pacific Drug Repurposing Market Outlook
8.1. Regional Revenue and Forecast
8.2. By Therapeutic Area
8.3. By Development Stage
8.4. By Drug Molecule Type
8.5. By Route of Administration
8.6. By End User
8.7. Country-level Analysis
9. South and Central America Drug Repurposing Market Outlook
9.1. Regional Revenue and Forecast
9.2. By Therapeutic Area
9.3. By Development Stage
9.4. By Drug Molecule Type
9.5. By Route of Administration
9.6. By End User
9.7. Country-level Analysis
10. Middle East and Africa Drug Repurposing Market Outlook
10.1. Regional Revenue and Forecast
10.2. By Therapeutic Area
10.3. By Development Stage
10.4. By Drug Molecule Type
10.5. By Route of Administration
10.6. By End User
10.7. Country-level Analysis
11. Competitive Intelligence
11.1. Competitive Landscape
11.2. Participant Strategies and Capabilities
11.3. Companies Mentioned
11.4. Partnership and Channel Opportunities
12. Appendix
12.1. Definitions and Abbreviations
12.2. Sources and Forecast Assumptions

Companies Mentioned

  • BenevolentAI
  • Healx
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Schrödinger
  • Atomwise
  • GSK
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • Roche
  • Sanofi
  • Bristol Myers Squibb
  • AstraZeneca
  • Bayer
  • Merck & Co.
  • Takeda

Table Information